Skip to main content

Table 2 Univariate and Multivariable Cox Proportional Hazard Models of PFS vs BMI

From: The complex relationship between body mass index and response to immune checkpoint inhibition in metastatic melanoma patients

   anti-CTLA-4 anti-PD-1 Combination
   HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value
Univariate Model Overweight (vs Normal BMI) 1.1(0.67,1.83) 0.7 1.58(0.78,3.19) 0.21 0.36(0.15,0.85) 0.02
Obesity (vs Normal BMI) 0.98(0.59,1.63) 0.93 1.49(0.71,3.13) 0.3 0.17(0.04,0.65) 0.01
Multivariable Model Overweight (vs Normal BMI) 0.97(0.56,1.69) 0.92 2.34(1.05,5.2) 0.04 0.5(0.15,1.71) 0.27
Obesity (vs Normal BMI) 1.16(0.7,1.94) 0.57 2.46(1.03,5.89) 0.04 0.18(0.05,0.74) 0.02
Female 0.94(0.59,1.51) 0.81 1.05(0.6,1.84) 0.85 1.8(0.72,4.49) 0.21
Age at Treatment Initiation 1(0.98,1.01) 0.77 0.99(0.97,1.01) 0.28 0.99(0.95,1.03) 0.67
Stage IV at Treatment Initiation(vs Stage III) 3(1.07,8.41) 0.04 0.88(0.3,2.64) 0.82 0.19(0.02,1.62) 0.13
ECOG Status 1.78(1.22,2.6) 0.003 2.67(1.65,4.31) 0.003 3.02(1.44,6.32) <.001
LDH High 1.16(0.74,1.82) 0.52 2.25(1.08,4.7) 0.03 1.45(0.65,3.23) 0.36
Number of Metastatic Sites 1.21(1.04,1.4) 0.02 1.11(0.91,1.36) 0.29 0.94(0.7,1.25) 0.68
BRAF Mutated 0.86(0.37,2) 0.73 0.43(0.12,1.6) 0.21 1.83(0.61,5.54) 0.28